Administration USFaD: Warning Letters and Test Results for Cannabidiol-Related Products. Vol 4-15-2020, 2019.

Fibromyalgia.

Ann Intern Med. 172: ITC33-ITC48

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.

Journal of the Royal Statistical Society. 57: 289-300

Pain Management: Assembling a Tool Kit, Building a Life.

JAMA. 320: 2201-2202Boehnke KF Gagnier JJ Matallana L Williams DA.

Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.

J Pain. 22: 556-566

Boehnke KF, Gagnier JJ, Matallana L, Williams DA. Substituting Cannabidiol for Opioids and Pain Medications Among Individuals with Fibromyalgia: a Large Online Survey. Published online May 12, 2021. doi: 10.1016/j.jpain.2021.04.011

Boehnke KF Gangopadhyay S Clauw DJ Haffajee RL.

Qualifying Conditions Of Medical Cannabis License Holders In The United States.

Health Aff (Millwood). 38: 295-302Boehnke KF Litinas E Clauw DJ.

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain.

J Pain. 17: 739-744Boehnke KF Scott JR Litinas E Sisley S Clauw DJ Goesling J Williams DA.

Cannabis Use Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with Chronic Pain.

J Pain. 20: 1362-1372Boehnke KF Scott JR Litinas E Sisley S Williams DA Clauw DJ.

Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain.

J Pain. 20: 830-841Bonn-Miller MO Loflin MJE Thomas BF Marcu JP Hyke T Vandrey R

Labeling Accuracy of Cannabidiol Extracts Sold Online.

JAMA. 318: 1708-1709

Brenan M: 14% of Americans Say They Use CBD Products. Available at: https://news.gallup.com/poll/263147/americans-say-cbd-products.aspx Accessed 4-21-2020, 2020

Capano A Weaver R Burkman E.

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study.

Postgrad Med. : 1-6

Hypnotic and antiepileptic effects of cannabidiol.

J Clin Pharmacol. 21: 417S-427S

Casey SL, Atwal N, Vaughan CW: Cannabis constituent synergy in a mouse neuropathic pain model, 2017.

Cash MC Cunnane K Fan C Romero-Sandoval EA.

Mapping cannabis potency in medical and recreational programs in the United States.

PLoS One. 15e0230167

Pain management: Fibromyalgia drugs are 'as good as it gets' in chronic pain.

Nat Rev Rheumatol. 6: 439-440

Fibromyalgia: a clinical review.

JAMA. 311: 1547-1555Corroon J MacKay D Dolphin W.

Labeling of Cannabidiol Products: A Public Health Perspective. Cannabis and Cannabinoid Research.

A Cross-Sectional Study of Cannabidiol Users.

Cannabis Cannabinoid Res. 3: 152-161Crippa JA Derenusson GN Ferrari TB Wichert-Ana L Duran FL Martin-Santos R Simoes MV Bhattacharyya S Fusar-Poli P Atakan Z Santos Filho A Freitas-Ferrari MC McGuire PK Zuardi AW Busatto GF Hallak JE

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

J Psychopharmacol. 25: 121-130

Medical Fraud, mislabeling, Contamination: all Common in CBD Products.

Missouri Law Review. Fedorova EV Wong CF Ataiants J Iverson E Conn B Lankenau SE.

Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.

Drug and Alcohol Dependence. Fitzcharles MA Rampakakis E Sampalis J Shir Y Cohen M Starr M Hauser W.

Medical Cannabis Use by Rheumatology Patients Following Recreational Legalization: A Prospective Observational Study of 1000 Patients in Canada.

ACR Open Rheumatol. Fiz J Duran M Capella D Carbonell J Farre M.

Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life.

PLoS One. 6: e18440

Foundation A: Patients Tell Us About CBD Use.

() ()Goodman S Wadsworth E Schauer G Hammond D.

Use and Perceptions of Cannabidiol Products in Canada and in the United States.

Cannabis and Cannabinoid Research. Gurley BJ Murphy TP Gul W Walker LA ElSohly M.

Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.

J Diet. Haug NA Kieschnick D Sottile JE Babson KA Vandrey R MO Bonn-Miller

Training and Practices of Cannabis Dispensary Staff.

Cannabis Cannabinoid Res. 1: 244-251Hauser W Petzke F Sommer C.

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome.

J Pain. 11: 505-521Hurd YL Spriggs S Alishayev J Winkel G Gurgov K Kudrich C Oprescu AM Salsitz E.

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.

Am J Psychiatry. 176: 911-922Kaufmann CN Kim A Miyoshi M Han BH.

Patterns of Medical Cannabis Use Among Older Adults from a Cannabis Dispensary in New York State.

Cannabis and Cannabinoid Research. Leas EC Nobles AL Caputi TL Dredze M Smith DM Ayers JW.

Trends in Internet Searches for Cannabidiol (CBD) in the United States.

JAMA Netw Open. 2e1913853

Practical considerations in medical cannabis administration and dosing.

Eur J Intern Med. 49: 12-19

Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders.

Front Psychol. 10: 2466

Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems.

J Cannabis Res. 3Montoya Z Conroy M Vanden Heuvel BD Pauli CS Park SH

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol.

Front Pharmacol. 11571832

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Br J Pharmacol. 163: 1344-1364Schrepf A Williams DA Gallop R Naliboff BD Basu N Kaplan C Harper DE Landis JR Clemens JQ Strachan E Griffith JW Afari N Hassett A Pontari MA Clauw DJ Harte SE Network MR.

Sensory sensitivity and symptom severity represent unique dimensions of chronic pain: a MAPP Research Network study.

Pain. 159: 2002-2011Shannon S Lewis N Lee H Hughes S.

Cannabidiol in Anxiety and Sleep: A Large Case Series.

Perm J. 23: 18-041Skrabek RQ Galimova L Ethans K Perry D.

Nabilone for the treatment of pain in fibromyalgia.

J Pain. 9: 164-173van de Donk T Niesters M Kowal MA Olofsen E Dahan A van Velzen M.

An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.

Pain. 160: 860-869Vilches JR Taylor MB Filbey FM.

A Multiple Correspondence Analysis of Patterns of CBD Use in Hemp and Marijuana Users.

Frontiers in Psychiatry. 11Volkow ND Baler RD Compton WM Weiss SR.

Adverse health effects of marijuana use.

N Engl J Med. 370: 2219-2227Wakshlag JJ Cital S Eaton SJ Prussin R Cannabinoid Hudalla C.

Terpene, and Heavy Metal Analysis of 29 Over-the-Counter Commercial Veterinary Hemp Supplements.

Vet Med (Auckl). 11: 45-55Ware MA Fitzcharles MA Joseph L Shir Y.

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.

Anesth Analg. 110: 604-610

Functional somatic syndromes: sensitivities and specificities of self-reports of physician diagnosis.

Psychosom Med. 74: 891-895Warren JW Clauw DJ Langenberg P.

Prognostic factors for recent-onset interstitial cystitis/painful bladder syndrome.

BJU Int. 111: E92-E97Warren JW Howard FM Cross RK Good JL Weissman MM Wesselmann U Langenberg P Greenberg P Clauw DJ.

Antecedent nonbladder syndromes in case-control study of interstitial cystitis/painful bladder syndrome.

Urology. 73: 52-57Wheeler M Merten JW Gordon BT Hamadi H.

CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

Subst Use Misuse. 55: 1138-1145Whiting PF Wolff RF Deshpande S Di Nisio M Duffy S Hernandez AV Keurentjes JC Lang S Misso K Ryder S Schmidlkofer S Westwood M Kleijnen J.

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

JAMA. 313: 2456-2473

Phenotypic Features of Central Sensitization.

J Appl Biobehav Res. 23

Advances in the assessment of fibromyalgia.

Rheum Dis Clin North Am. 35: 339-357Wolfe F Clauw DJ Fitzcharles MA Goldenberg DL Hauser W Katz RS Mease P Russell AS Russell IJ Winfield JB.

Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia.

J Rheumatol. 38: 1113-1122Zuardi AW Rodrigues NP Silva AL Bernardo SA Hallak JEC Guimaraes FS Crippa JAS.

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.

Front Pharmacol. 8: 259